Anesthetics:
Indications for: PRECEDEX in Sodium Chloride
For sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. For sedation of non-intubated adult patients prior to and/or during surgical and other procedures. For sedation of non-intubated pediatric patients aged 1 month to <18 years prior to and during non-invasive procedures.
Adult Dosage:
Individualize. Give by continuous infusion not to exceed 24hrs. Initiation of ICU sedation: loading infusion of 1mcg/kg over 10mins; patients converting from alternate sedative therapy: a loading dose may not be required; >65yrs, hepatic impairment: reduce dose. Maintenance of ICU sedation: 0.2–0.7mcg/kg/hr; >65yrs, hepatic impairment: reduce dose. Initiation of procedural sedation: loading infusion of 1mcg/kg over 10mins, less invasive procedures: 0.5mcg/kg over 10mins; awake fiberoptic intubation patients: loading infusion of 1mcg/kg over 10mins; >65yrs: loading infusion of 0.5mcg/kg over 10mins; hepatic impairment: reduce dose. Maintenance of procedural sedation: initially 0.6mcg/kg/hr and titrated to achieve desired effect with doses ranging from 0.2–1mcg/kg/hr; awake fiberoptic intubation patients: 0.7mcg/kg/hr until endotracheal tube is secured; >65yrs, hepatic impairment: reduce dose.
Children Dosage:
Initiation of ICU or other surgical procedural sedation: not established. Initiation of sedation during non-invasive procedures: <1month: not established. Individualize. Give by continuous infusion not to exceed 24hrs. 1month–<2yrs: loading infusion of 1.5mcg/kg over 10mins; 2yrs–<18yrs: loading infusion of 2mcg/kg over 10mins; consider dose reduction if clinically indicated. Maintenance of sedation during non-invasive procedures (1month–<18yrs): initially 1.5mcg/kg/hr and titrated to achieve desired effect with doses ranging from 0.5–1.5mcg/kg/hr; titrate as clinically warranted based on response.
PRECEDEX in Sodium Chloride Warnings/Precautions:
Should be administered by persons skilled in management of patients in intensive care or operating room setting. Advanced heart block and/or severe ventricular dysfunction. Hypovolemia, diabetes, chronic hypertension, elderly: increased risk of bradycardia and hypotension. Withdrawal symptoms (adults: within 24-48hrs after infusion discontinued; children: after infusions <2hrs). Discontinue if hyperthermia or pyrexia is suspected; monitor. Hepatic impairment. Pregnancy. Nursing mothers: monitor infants.
See Also:
PRECEDEX in Sodium Chloride Classification:
Alpha-2 agonist.
PRECEDEX in Sodium Chloride Interactions:
Additive effects with other vasodilators, negative chronotropic agents, anesthetics, sedatives, hypnotics, opioids; consider reducing dose. Incompatible with amphotericin B or diazepam; avoid co-administration.
Adverse Reactions:
Hypotension, bradycardia, dry mouth, bradypnea, hypertension; sinus arrest, transient hypertension (w. loading dose).
Drug Elimination:
Renal. Half-life: ~2 hours.
Generic Drug Availability:
YES
How Supplied:
Single-dose vials (100mcg/mL)—25 (2mL); Single-dose vials (4mcg/mL)—10 (each 20mL); Single-dose bottles (4mcg/mL)—20 (50mL), 10 (100mL), 1 (250mL)
